Tocqueville Asset Management L.P. bought a new position in Charles River Laboratories Intl. Inc (NYSE:CRL) in the fourth quarter, Holdings Channel reports. The institutional investor bought 2,760 shares of the medical research company’s stock, valued at approximately $302,000.

Other institutional investors also recently made changes to their positions in the company. Tower Research Capital LLC TRC increased its stake in Charles River Laboratories Intl. by 1,071.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 1,054 shares of the medical research company’s stock worth $115,000 after purchasing an additional 964 shares during the period. Ladenburg Thalmann Financial Services Inc. increased its stake in Charles River Laboratories Intl. by 69.0% in the 3rd quarter. Ladenburg Thalmann Financial Services Inc. now owns 1,342 shares of the medical research company’s stock worth $145,000 after purchasing an additional 548 shares during the period. Advisor Group Inc. increased its stake in Charles River Laboratories Intl. by 159.4% in the 3rd quarter. Advisor Group Inc. now owns 1,538 shares of the medical research company’s stock worth $165,000 after purchasing an additional 945 shares during the period. Zions Bancorporation purchased a new position in Charles River Laboratories Intl. in the 3rd quarter worth approximately $212,000. Finally, ETRADE Capital Management LLC purchased a new position in Charles River Laboratories Intl. in the 4th quarter worth approximately $218,000. 99.90% of the stock is currently owned by institutional investors and hedge funds.

How to Become a New Pot Stock Millionaire

Charles River Laboratories Intl. Inc (CRL) opened at $114.19 on Wednesday. The company has a debt-to-equity ratio of 1.06, a quick ratio of 1.54 and a current ratio of 1.78. Charles River Laboratories Intl. Inc has a 12 month low of $86.44 and a 12 month high of $119.05. The stock has a market capitalization of $5,463.81, a P/E ratio of 44.96, a PEG ratio of 1.61 and a beta of 0.71.

Charles River Laboratories Intl. (NYSE:CRL) last posted its earnings results on Tuesday, February 13th. The medical research company reported $1.40 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.26 by $0.14. Charles River Laboratories Intl. had a return on equity of 26.14% and a net margin of 6.64%. The firm had revenue of $478.50 million for the quarter, compared to analysts’ expectations of $475.02 million. During the same period in the previous year, the firm earned $1.21 earnings per share. The business’s revenue was up 2.5% compared to the same quarter last year. sell-side analysts anticipate that Charles River Laboratories Intl. Inc will post 5.77 EPS for the current fiscal year.

In other news, insider Birgit Girshick sold 9,893 shares of the business’s stock in a transaction that occurred on Tuesday, March 6th. The stock was sold at an average price of $109.10, for a total transaction of $1,079,326.30. Following the transaction, the insider now directly owns 26,470 shares of the company’s stock, valued at $2,887,877. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director George M. Milne, Jr. sold 7,740 shares of the business’s stock in a transaction that occurred on Friday, March 9th. The shares were sold at an average price of $115.00, for a total value of $890,100.00. Following the transaction, the director now directly owns 36,760 shares in the company, valued at $4,227,400. The disclosure for this sale can be found here. Insiders have sold 207,720 shares of company stock worth $8,455,637 over the last three months. Insiders own 2.20% of the company’s stock.

A number of equities analysts have commented on the company. TheStreet cut Charles River Laboratories Intl. from an “a-” rating to a “c+” rating in a research note on Tuesday, February 13th. Credit Suisse Group reaffirmed a “hold” rating and issued a $108.00 price target on shares of Charles River Laboratories Intl. in a research note on Thursday, February 15th. Barclays reaffirmed a “hold” rating and issued a $110.00 price target on shares of Charles River Laboratories Intl. in a research note on Friday, February 16th. Royal Bank of Canada set a $116.00 price target on Charles River Laboratories Intl. and gave the stock a “hold” rating in a research note on Tuesday, February 13th. Finally, SunTrust Banks cut Charles River Laboratories Intl. from a “buy” rating to a “hold” rating and lifted their price target for the stock from $107.89 to $111.00 in a research note on Monday, January 22nd. They noted that the move was a valuation call. Seven investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $118.08.

ILLEGAL ACTIVITY WARNING: This article was first posted by Daily Political and is the sole property of of Daily Political. If you are reading this article on another domain, it was stolen and reposted in violation of US and international copyright & trademark law. The legal version of this article can be read at https://www.dailypolitical.com/2018/03/14/tocqueville-asset-management-l-p-buys-new-stake-in-charles-river-laboratories-intl-inc-crl.html.

Charles River Laboratories Intl. Company Profile

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories Intl. Inc (NYSE:CRL).

Institutional Ownership by Quarter for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.